Invitae Corporation (NVTAQ)
Aug 7, 2024 - NVTAQ was delisted (reason: shares cancelled)
0.0003
-0.0001 (-25.00%)
Inactive · Last trade price on Aug 7, 2024

Company Description

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally.

The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.

It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012.

Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.

The plan was later approved as Chapter 11 liquidation on August 2, 2024.

Invitae Corporation
Invitae logo
CountryUnited States
Founded2010
IPO DateFeb 12, 2015
IndustryDiagnostics & Research
SectorHealthcare
Employees1,700
CEOKenneth D. Knight

Contact Details

Address:
1400 16th Street
San Francisco, California 94103
Phone(415) 374-7782
Websiteinvitae.com

Stock Details

Ticker SymbolNVTAQ
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001501134
CUSIP Number46185L103
ISIN NumberUS46185L1035
Employer ID27-1701898
SIC Code8071

Key Executives

NamePosition
Kenneth D. KnightPresident, Chief Executive Officer and Director
Dr. Randal W. Scott Ph.D.Co-Founder and Chairman of the Board
Thomas R. BridaGeneral Counsel, Chief Compliance Officer and Secretary
Ana J. SchrankChief Accounting Officer and Chief Financial Officer
Dr. David B. Sholehvar M.D.Chief Operating Officer
Hoki LukHead of Investor Relations and Capital Markets and Corporate Development
Shelly D. GuyerChief Sustainability Officer
Desarie FrenchChief Talent Officer
Dr. W. Michael Korn M.D.Chief Medical Officer
Robert GuigleyChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Aug 8, 20248-KCurrent Report
Jul 31, 20248-KCurrent Report
Jul 1, 20248-KCurrent Report
Jun 4, 20248-KCurrent Report
May 2, 20248-KCurrent Report
Apr 4, 20248-KCurrent Report
Mar 6, 20248-KCurrent Report
Feb 21, 202425-NSEFiling
Feb 14, 20248-KCurrent Report
Feb 13, 2024SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individuals